Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Beyond black‐box AI: Comparing ChatGPT‐4 interpretability and accuracy to CNNs in melanocytic lesions diagnosis
0
Zitationen
11
Autoren
2026
Jahr
Abstract
BACKGROUND: Artificial intelligence (AI) algorithms have advanced and recently shown high accuracy in diagnosing skin cancer from dermoscopic images. This study compared the diagnostic performance of the large language model ChatGPT-4 with that of specialized convolutional neural network (CNN)-based models in analyzing melanocytic lesions. PATIENTS AND METHODS: A cross-sectional comparative study was conducted using 117 dermoscopic images. The performance of ChatGPT-4 was assessed under two conditions: diagnosing lesions directly without annotations and diagnosing after annotating dermoscopic features. Results were compared with CNN-based models (YPSONO and ResNet) and human expert evaluations. The confusion matrices of all the models were calculated in addition to the diagnostic accuracy, sensitivity, specificity, and interobserver agreement (Cohen's Kappa). RESULTS: ChatGPT-4 achieved 92 % sensitivity, 89 % specificity, and an accuracy of 89.7 % in direct diagnosis. When annotations were required, sensitivity and specificity dropped to 68 % and 64 %, respectively. Agreement with experts on dermoscopic patterns was minimal (Cohen's Kappa = 0.13). ChatGPT-4 outperformed CNN models in direct diagnosis but exhibited notable limitations in describing dermoscopic features. CONCLUSIONS: ChatGPT-4 demonstrated promising potential for accurate melanoma versus nevus classification without annotations, surpassing CNN-based models. However, its limited ability to describe dermoscopic features accurately highlights the need for further research and training.
Ähnliche Arbeiten
Dermatologist-level classification of skin cancer with deep neural networks
2017 · 13.594 Zit.
Tumor Angiogenesis: Therapeutic Implications
1971 · 10.121 Zit.
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
2011 · 7.680 Zit.
Pembrolizumab versus Ipilimumab in Advanced Melanoma
2015 · 5.827 Zit.
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
2017 · 5.376 Zit.
Autoren
Institutionen
- Tel Aviv University(IL)
- Rabin Medical Center(IL)
- Pontificia Universidad Católica de Chile(CL)
- Ono Academic College(IL)
- Sheba Medical Center(IL)
- Rappaport Family Institute for Research in the Medical Sciences(IL)
- Poriya Medical Center(IL)
- Rutgers, The State University of New Jersey(US)
- Rutgers Sexual and Reproductive Health and Rights(NL)
- Environmental and Occupational Health Sciences Institute(US)
- Rambam Health Care Campus(IL)